Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma
Clinical trial NCT07302516 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07302516
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-25
- Primary completion
- 2028-12-01
- Enrollment
- 636
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.